7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data

      review-article
      1 , 2
      HIV/AIDS (Auckland, N.Z.)
      Dove Medical Press
      antiretroviral therapy, pregnancy, birth defects

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An increasing number of HIV-infected women of childbearing age are initiating antiretroviral therapy (ART) worldwide. This review aims to discuss updated data of the eligible ART regimens and their role in inducing birth defects in utero. Zidovudine and lamivudine plus a non-nucleoside reverse-transcriptase inhibitor or protease inhibitor (PI) is the first-line regimen applied. The role of zidovudine exposition monotherapy or associated with other ART in inducing birth defects remains inconclusive. The main organ systems involved are genitourinary and cardiovascular. For HIV-infected pregnant women, World Health Organization (WHO) guidelines up to 2010 recommend the same group of drugs that are prescribed to nonpregnant women. The exception is efavirenz, which has been associated with an increase in the risk of teratogenicity. Increased rates of birth defects were found in large cohorts and computational studies conducted recently in infants exposed to efavirenz-containing regimens. The combination of zidovudine and lamivudine and lopinavir/ritonavir is one of the most used ART regimens for prevention of mother-to-child-transmission. Conflicting data about the role of PI exposure in utero and birth defects have been reported. However, a reduced number of studies evaluating the role of PI in inducing birth defects in women are available. An association between prematurity and PI exposure in pregnancy was extensively described. Some questions arise due to the tendency of initiating ART early in the life of HIV-infected individuals or those at risk of infection. Longtime exposure to different ART regimens and the potential effect of birth-defect induction in pregnancy are not completely understood. Developing regions harbor the highest numbers of women of reproductive age exposed to ART. Most of the largest and expressive data come from developed countries, and could not be sufficiently representative of pregnant women living in developing countries.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis.

          To determine magnitude and reasons of loss to program and poor antiretroviral prophylaxis coverage in prevention of mother-to-child transmission (PMTCT) programs in sub-Saharan Africa. Systematic review and meta-analysis. We searched PubMed and Embase databases for PMTCT studies in sub-Saharan Africa published between January 2002 and March 2012. Outcomes were the percentage of pregnant women tested for HIV, initiating antiretroviral prophylaxis, having a CD4 cell count measured, and initiating antiretroviral combination therapy (cART) if eligible. In children outcomes were early infant diagnosis for HIV, and cART initiation. We combined data using random-effects meta-analysis and identified predictors of uptake of interventions. Forty-four studies from 15 countries including 75,172 HIV-infected pregnant women were analyzed. HIV-testing uptake at antenatal care services was 94% [95% confidence intervals (CIs) 92-95%] for opt-out and 58% (95% CI 40-75%) for opt-in testing. Coverage with any antiretroviral prophylaxis was 70% (95% CI 64-76%) and 62% (95% CI 50-73%) of pregnant women eligible for cART received treatment. Sixty-four percent (95% CI 48-81%) of HIV exposed infants had early diagnosis performed and 55% (95% CI 36-74%) were tested between 12 and 18 months. Uptake of PMTCT interventions was improved if cART was provided at the antenatal clinic and if the male partner was involved. In sub-Saharan Africa, uptake of PMTCT interventions and early infant diagnosis is unsatisfactory. An integrated family-centered approach seems to improve retention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Early marriage and sexual and reproductive health vulnerabilities of young women: a synthesis of recent evidence from developing countries.

            K Santhya (2011)
            To review current evidence on the links between early marriage and health-related outcomes for young women and their children. Every third young woman in the developing countries excluding China continues to marry as a child, that is before age 18. Recent studies reiterate the adverse health consequences of early marriage among young women and their children even after a host of confounding factors are controlled. The current evidence is conclusive with regard to many indicators: unintended pregnancy, pregnancy-related complications, preterm delivery, delivery of low birth weight babies, fetal mortality and violence within marriage. However, findings present a mixed picture with regard to many other indicators, the risk of HIV and the risk of neonatal, infant and early childhood mortality, for example. The findings call for further examination of the health consequences of early marriage. What are even less clear are the pathways through which the associations between early marriage and adverse outcomes take place. There is a need for research that traces these links. At the same time, findings argue strongly for programmatic measures that delay marriage and recognize the special vulnerabilities of married adolescent girls. (C) 2011 Lippincott Williams & Wilkins, Inc.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Combination antiretroviral use and preterm birth.

              Use of antiretroviral drugs (ARVs) during pregnancy has been associated with higher risk of preterm birth.
                Bookmark

                Author and article information

                Journal
                HIV AIDS (Auckl)
                HIV AIDS (Auckl)
                HIV/AIDS (Auckland, N.Z.)
                Dove Medical Press
                1179-1373
                2013
                01 August 2013
                : 5
                : 181-189
                Affiliations
                [1 ]Immunology Department, University of Oeste Paulista, Presidente Prudente, São Paulo, Brazil
                [2 ]Infectious Diseases Department, Hospital Ipiranga, São Paulo, S P, Brazil
                Author notes
                Correspondence: Luiz Euribel Prestes-Carneiro, Immunology Department, University of Western São Paulo, 700 Rua José Bongiovani, Cidade Universitária, Presidente Prudente, São Paulo 19050-680, Brazil, Phone/fax +55 18 229 1013, Email luiz@ 123456unoeste.br
                Article
                hiv-5-181
                10.2147/HIV.S15542
                3738258
                23943659
                af84805b-ea63-48b9-8c59-abb355666228
                © 2013 Prestes-Carneiro, publisher and licensee Dove Medical Press Ltd

                This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

                History
                Categories
                Review

                Infectious disease & Microbiology
                antiretroviral therapy,pregnancy,birth defects
                Infectious disease & Microbiology
                antiretroviral therapy, pregnancy, birth defects

                Comments

                Comment on this article